argus

Natco Pharma Ltd.

NSE: NATCOPHARMINE987B0102615,101 Cr

Timeline

Time (IST)TypeMEventSrc
20 Nov, 04:39 pmNatco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Earnings Call Transcriptbse
20 Nov, 04:35 pmNatco Pharma Limited has informed the Exchange about Transcriptnse
15 Nov, 12:09 pmNatco Pharma Limited has informed the Exchange about Link of Recordingnse
15 Nov, 11:50 amNatco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcomebse
14 Nov, 03:10 pmNatco Pharma Limited has informed the Exchange about Presentationnse
14 Nov, 03:07 pmNatco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Investor Presentationbse
14 Nov, 01:46 pmNatco Pharma Ltd - 524816 - Corporate Action-Board approves Dividendbse
14 Nov, 01:44 pmNatco Pharma Ltd - 524816 - Financial Results For The Quarter And Half Year Ended 30Th September, 2025bse
14 Nov, 01:33 pmNatco Pharma Limited has informed the Exchange that Record date for the purpose of 2nd Interim Dividend for the FY 2025-26 is 20-Nov-2025.nse
14 Nov, 01:27 pmoutcome of Board Meeting held on 14th November, 2025nse
12 Nov, 03:07 pmNatco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
12 Nov, 03:02 pmNatco Pharma Limited has informed the Exchange regarding a press release dated November 12, 2025, titled "Adcock Ingram Holdings Limited completes delisting from Johannesburg Stock Exchange and NATCO Pharma Limited acquires 35.75% stake".nse
11 Nov, 12:50 pmNatco Pharma Limited has informed the Exchange about Revised intimation earnings call for the quarter and half year ended 30th September, 2025nse
07 Nov, 12:26 pmNatco Pharma Limited has informed the Exchange about Earnings Call to discuss Q2FY26 Un-audited Financial Resultsnse
07 Nov, 11:48 amNatco Pharma Ltd - 524816 - Board Meeting Intimation for Considering And Approve The Financial Results For The Period Ended September 30, 2025 And 2Nd Interim Dividend For The Financial Year Ending 2025-26bse
31 Oct, 09:07 amNatco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
31 Oct, 09:02 amNatco Pharma Limited has informed the Exchange regarding a press release dated October 31, 2025, titled "NATCO announces launch of its Everolimus tablets, 1 mg, (generic of Zortress®)".nse
17 Oct, 05:11 pmNatco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
17 Oct, 05:08 pmNatco Pharma Limited has informed the Exchange regarding a press release dated October 17, 2025, titled "Legal update regarding Risdiplam ".nse
10 Oct, 01:09 pmNatco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
10 Oct, 01:07 pmNatco Pharma Limited has informed the Exchange regarding a press release dated October 10, 2025, titled "Updates on proposed acquisition of shares in Adcock Ingram Holdings Limited".nse
09 Oct, 05:36 pmNatco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
09 Oct, 05:32 pmNatco Pharma Limited has informed the Exchange regarding a press release dated October 09, 2025, titled "Legal update regarding Risdiplam Commercial Appellate Division of the Hon ble Delhi High Court Dismissed Appeal ".nse
09 Oct, 04:45 pmNatco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Change in Managementbse
09 Oct, 04:40 pmNatco Pharma Limited has informed the Exchange regarding Appointment of Mr. G. Vijay Kiran Kumar as Vice President Corporate Quality Assurance (Formulations) of the company w.e.f. October 09, 2025.nse
03 Oct, 09:56 amNatco Pharma Ltd - 524816 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011bse
30 Sept, 05:32 pmNatco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Change in Managementbse
30 Sept, 05:28 pmNatco Pharma Limited has informed the Exchange regarding Cessation of Mr Dr. Santhan Gopalakrishnan Vaidyanathan as Other of the company w.e.f. September 30, 2025.nse
25 Sept, 10:54 amNatco Pharma Limited has informed the Exchange about General Updatesnse
25 Sept, 10:47 amNatco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Meeting Updatesbse
19 Sept, 10:53 amNatco Pharma Ltd - 524816 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011bse
18 Sept, 09:50 amNatco Pharma Limited has informed the Exchange regarding a press release dated September 18, 2025, titled "NATCO's Pharma division located in Kothur, Hyderabad, India has now received Establishment Inspection Report (EIR) classifying the facility as "Voluntary Action Indicated (VAI)" from the U.S. Food and Drug Administration (FDA)nse
18 Sept, 09:49 amNatco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
15 Sept, 05:50 pmNatco Pharma Ltd - 524816 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011bse
10 Sept, 11:23 amNatco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Releasebse
10 Sept, 11:19 amNatco Pharma Limited has informed the Exchange regarding a press release dated September 10, 2025, titled "Update".nse